Search

DEA Says Marijuana Rescheduling Process Is Still Stalled Six Months Into Trump Administration < Back DEA Says Marijuana Rescheduling Process Is Still Stalled... Jul 8, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Drug Enforcement Administration (DEA) has again notified an agency judge that the marijuana rescheduling process remains stalled under the Trump administration. It’s been six months since DEA Administrative Law Judge (ALJ) John Mulrooney temporarily paused hearings on a proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) that was initiated under the Biden administration. And in a joint report to the judge submitted on Monday, DEA attorneys and rescheduling proponents said they’re still at an impasse. “To date, Movants’ interlocutory appeal to the Acting Administrator regarding their Motion to Reconsider remains pending with the Acting Administrator. No briefing schedule has been set,” the notice says. This comes 90 days after both parties sent the judge an identical update, albeit when a different acting administrator was in charge. DEA and the witnesses involved in the interlocutory appeal must provide another update in 90 days. But for the time being, any action on the proposed rule to reschedule marijuana is evidently contingent on DEA Acting Administrator Robert Murphy. Murphy’s appointment as acting administrator wasn’t widely publicized, but he’s replaced Derek Maltz—who subscribes to the “gateway drug” theory for marijuana— in the role as the Senate considers confirming President Donald Trump’s pick to lead the agency, Terrance Cole. Whereas Maltz, the former acting administrator, made his opposition to cannabis reform known in numerous social media posts and TV interviews before taking on the leadership role, Murphy’s position on the issue is less clear—though it is notable that he did speak at an event hosted by prohibitionist organization Smart Approaches to Marijuana in 2018. A summary of the appearance from the group says he “addressed the conference on the reality that black markets are thriving off of marijuana originating in states that legalized the substance and took a moment to remind everyone that medical and recreational marijuana is still illegal under federal law.” In May, a Senate committee advanced the nomination of Cole to become DEA administrator amid the ongoing review of the marijuana rescheduling proposal that he has so far refused to commit to enacting. Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—said in response to senators’ written questions that he would “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.” However, during an in-person hearing before the Senate Judiciary Committee in April, he said examining the rescheduling proposal will be “one of my first priorities” if he was confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see. Mulrooney, the agency judge, initially agreed to delay the proceedings after several pro-rescheduling parties requested a leave to file an interlocutory appeal amid allegations that certain DEA officials conspired with anti-rescheduling witnesses who were selected for the hearing. The DEA judge initially agreed to delay the proceedings after several pro-rescheduling parties requested a leave to file an interlocutory appeal amid allegations that certain DEA officials conspired with anti-rescheduling witnesses who were selected for the hearing. Originally, hearings were set to commence on January 21, but those were cancelled when Mulrooney granted the appeal motion. He ordered DEA and the witnesses to provide a joint status update within 90 days, which would be this coming Sunday. The appeal came after the judge denied a motion that sought DEA’s removal from the rescheduling proceedings altogether, arguing that it is improperly designated as the chief “proponent” of the proposed rule given the allegations of ex parte communications with anti-rescheduling witnesses that “resulted in an irrevocable taint” to the process. Meanwhile, the Justice Department told a federal court in January that it should pause a lawsuit challenging DEA’s marijuana rescheduling process after Mulrooney canceled the hearings. Also in January, Mulrooney condemned DEA over its “unprecedented and astonishing” defiance of a key directive related to evidence it is seeking to use in the marijuana rescheduling proposal. At issue was DEA’s insistence on digitally submitting tens of thousands of public comments it received in response to the proposed rule to move cannabis to Schedule III. Mulrooney hasn’t been shy about calling out DEA over various procedural missteps throughout this rescheduling process. For example, in December he criticized the agency for making a critical “blunder” in its effort to issue subpoenas to force Food and Drug Administration (FDA) officials to testify in hearings—but he allowed the agency to fix the error and ultimately granted the request. Relatedly, a federal judge also dismissed a lawsuit seeking to compel DEA to turn over its communications with the anti-cannabis organization. Mulrooney had separately denied a cannabis research company’s request to allow it to add a young medical marijuana patient and advocate as a witness in the upcoming rescheduling hearing. Also, one of the nation’s leading marijuana industry associations asked the judge to clarify whether it will be afforded the opportunity to cross-examine DEA during the upcoming hearings on the cannabis rescheduling proposal. Further, a coalition of health professionals that advocates for cannabis reform recently asked that the DEA judge halt future marijuana rescheduling hearings until a federal court is able to address a series of allegations they’re raising about the agency’s witness selection process. The rescheduling proceedings have generated significant public interest. While moving marijuana to Schedule III wouldn’t federally legalize it, the reform would free up licensed cannabis businesses to take federal tax deductions and remove certain research barriers. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Meanwhile, two GOP senators introduced a bill in February that would continue to block marijuana businesses from taking federal tax deductions under Internal Revenue Service (IRS) code 280E—even if it’s ultimately rescheduled. Beyond the hearing delays, another complicating factor is the change in leadership at DEA under the Trump administration. U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. was previously vocal about his support for legalizing cannabis, as well as psychedelics therapy. But during his Senate confirmation process in February, he said that he would defer to DEA on marijuana rescheduling in his new role. Separately, former Rep. Matt Gaetz (R-FL) was reportedly photographed reviewing a document that appears to be a draft contract to provide services—including “administration-related guidance”—to a firm affiliated with the major marijuana company Trulieve. The visible portion of the document describes a lucrative bonus if a certain “matter resolves,” with an “additional ‘Super Success Fee’” for other “exclusive policy remedies.” Last month, the former congressman reiterated his own support for rescheduling cannabis—suggesting in an interview with a Florida Republican lawmaker that the GOP could win more of the youth vote by embracing marijuana reform. Gaetz also said last month that Trump’s endorsement of a Schedule III reclassification was essentially an attempt to shore up support among young voters rather than a sincere reflection of his personal views about cannabis. A survey conducted by a GOP pollster affiliated with Trump that was released in April found that a majority of Republicans back a variety of cannabis reforms, including rescheduling. And, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter. Meanwhile, Trump picked former Florida Attorney General Pam Bondi (R) to run DOJ, and the Senate confirmed that choice. During her confirmation hearings, Bondi declined to say how she planned to navigate key marijuana policy issues. And as state attorney general, she opposed efforts to legalize medical cannabis. Amid the stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers recently reiterated that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges. Meanwhile, a newly formed coalition of professional athletes and entertainers, led by retired boxer Mike Tyson, sent a letter to Trump on Friday—thanking him for past clemency actions while emphasizing the opportunity he has to best former President Joe Biden by rescheduling marijuana, expanding pardons and freeing up banking services for licensed cannabis businesses. *Read the joint update to the DEA judge on the marijuana rescheduling process below:* *Photo courtesy of Brian Shamblen.* The post DEA Says Marijuana Rescheduling Process Is Still Stalled Six Months Into Trump Administration appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

< Back Wedding Cake (Indica) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) 4.6 123 Ratings average rating is 4.6 out of 5, based on 123 votes, Ratings $30.00 3.5g Order Now Description Wedding Cake is a Grade B indica strain with 27.2% THC, featuring a vanilla flavor. It offers relaxation, sleepiness, and happiness, ideal for evening relaxation or pain relief. Effects relaxed, sleepy, happy Previous Next Cheetah Piss (Sativa) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 172 Ratings average rating is 4.8 out of 5, based on 172 votes, Ratings Lemon Haze (Sativa) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 169 Ratings average rating is 4.8 out of 5, based on 169 votes, Ratings Forum Cookie (Indica) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 168 Ratings average rating is 4.8 out of 5, based on 168 votes, Ratings

Several U.S. cities are using cannabis tax revenues for Universal Basic Income (UBI) programs. Albuquerque is allocating $4.02 million annually to support a UBI program, providing $750 monthly payments to 80 households, and Rochester is utilizing cannabis tax revenues to sustain a UBI program with $500 monthly payments to 175 families. These initiatives aim to address economic disparities and provide stability to underserved communities. < Back Cannabis Tax Revenues Fuel Universal Basic Income Initiatives in U.S. Cities May 20, 2025 Staff Mary Jane Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Several U.S. cities are pioneering the use of cannabis tax revenues to fund Universal Basic Income (UBI) programs, aiming to address economic disparities and support communities historically affected by cannabis criminalization. *Albuquerque’s Groundbreaking UBI Program* Albuquerque, New Mexico, has launched a notable initiative by allocating $4.02 million annually from cannabis tax revenues to support a UBI program. Half of this funding is directed to the Office of Equity and Inclusion to provide $750 monthly payments to 80 households over three years, focusing on the International District and Westside neighborhoods. These areas were selected due to their economic challenges and historical impacts from cannabis criminalization. The remaining funds support youth-focused initiatives, including substance use prevention and recovery services . *Rochester’s Vision for Cannabis-Funded UBI* In Rochester, New York, Mayor Malik Evans has proposed utilizing cannabis tax revenues to sustain a UBI program that currently provides $500 monthly payments to 175 families. Initially funded by the American Rescue Plan, the program aims to transition to a more sustainable model through cannabis taxation. This approach seeks to address the wealth gap exacerbated by past cannabis-related prosecutions . *Broader Implications and Future Prospects* These initiatives reflect a growing trend of leveraging cannabis tax revenues for social equity programs. By redirecting funds from cannabis sales to support UBI programs, cities aim to rectify historical injustices and provide economic stability to underserved communities. As more municipalities explore similar models, cannabis taxation could become a pivotal tool in advancing economic equity nationwide. The post Cannabis Tax Revenues Fuel Universal Basic Income Initiatives in U.S. Cities appeared first on Merry Jane. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

Gov. JB Pritzker plans to regulate hemp-derived cannabinoid products if state lawmakers and industry advocates don't cooperate. < Back Illinois Governor Says ‘We Will Take Executive Action’ on Intoxicating Hemp Products Sep 17, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Gov. JB Pritzker said he will regulate hemp-derived cannabinoid products should state lawmakers and industry advocates remain ‘unwilling.’ < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

Cresco Labs Inc. announced plans to exit the California market as part of a strategic restructuring to strengthen its balance sheet and prioritize markets with higher margins and long-term growth potential. CEO Charlie Bachtell stated that... < Back Cresco Labs Exiting California Market as Part of ‘Strategic Restructuring’ Jul 24, 2025 TG Branfalt Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Cresco Labs Inc. on Monday announced plans to exit the California market as part of a “strategic restructuring” as part of a larger strategy by the company “to strengthen its balance sheet, increase cash flow and prioritize markets with the highest margins and long-term growth potential.” In a statement, Cresco Labs CEO and co-founder Charlie Bachtell said that “While California is the largest cannabis market in the world, the structural challenges – ranging from fragmented retail to price compression and the illicit market” combined with the company’s “lack of scaled footprint in the state,” have made “it extremely difficult to generate sustainable profitability.” “Capital is increasingly precious in this environment, and our focus is on deploying it where it earns the strongest return. … Exiting California allows us to reallocate capital and resources to our core markets and build out new markets where we see clear pathways for growth and shareholder value.” — Bachtell in a press release The Chicago, Illinois-based company indicated that it is “in active discussions” with potential buyers for its cultivation, manufacturing, and “select distribution operations” in California and expects to finalize a deal “within the next several quarters.” Cresco said it plans to retain full ownership of its FloraCal brand. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

Blunt DC WEBSITE MENU REVIEWS 1606 K Street Northwest, Washington, DC, USA About OVERALL 4.0 average rating is 4 out of 5 EXPERIENCE 4.1 average rating is 4.1 out of 5 QUALITY 4.0 average rating is 4 out of 5 SERVICE 3.9 average rating is 3.9 out of 5 SELECTION 4.1 average rating is 4.1 out of 5 PRICES 3.7 average rating is 3.7 out of 5 Blunt DC on K Street NW offers a no-nonsense approach to cannabis shopping. The dispensary focuses on providing essential flower, pre-rolls, and concentrates for busy urbanites. Its central location makes it a convenient stop for downtown professionals. The staff keeps interactions efficient while ensuring quality recommendations. Ideal for those seeking a quick, reliable cannabis source. Recent Reviews Check back soon Once posts are published, you’ll see them here. Trending Nearby Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Jokerz by Alt Sol - Green Theory DC This batch of Jokerz, cultivated by Alt Sol and currently available at Green Theory dispensary in Washington DC, is an indica-dominant st... Motorbreath by Alt Sol - Takoma Wellness Center This batch of Motorbreath, available at Takoma Wellness Center dispensary in Washington DC, is one of the latest creations by local craft... 1 2 3 4 5 best weed in DC (1,156) 1,156 posts DC flower (1,081) 1,081 posts DC I-71 (1,029) 1,029 posts terps (986) 986 posts DC Storefront (666) 666 posts heavy trichomes (653) 653 posts Indica Heavy Hybrid (607) 607 posts DC weed delivery (534) 534 posts starry trichomes (509) 509 posts Indica (473) 473 posts 50/50 Hybrid (415) 415 posts Sativa Dominant Hybrid (252) 252 posts Sativa (209) 209 posts Gelato (153) 153 posts DC Medical Marijuana (143) 143 posts Medical Marijuana (138) 138 posts Maryland Medical Marijuana (107) 107 posts Runtz (101) 101 posts Maryland Flower (99) 99 posts Elevated Lounge (95) 95 posts GSC (91) 91 posts alternative solutions (84) 84 posts Takoma Wellness Center (80) 80 posts The Gift Givers (78) 78 posts concentrate (74) 74 posts Maryland Recreational (70) 70 posts best weed in Maryland (69) 69 posts edibles (69) 69 posts Zkittles (69) 69 posts infused (59) 59 posts

A Connecticut hemp farmer has filed a federal lawsuit against the state, claiming that the cannabis industry's licensing rules, which prioritize social equity applicants, are discriminatory and unconstitutional. The suit argues that federal law prohibits excluding cannabis applicants based on location or residence, asserting that the state's program amounts to economic protectionism. The lawsuit also references a federal appeals court ruling that found part of New York’s cannabis social equity rules unconstitutional. < Back Connecticut Hemp Farmer Says State Cannabis Laws Are Discriminatory Oct 20, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A Connecticut hemp farmer has filed a federal lawsuit claiming that the state’s cannabis industry’s licensing rules are discriminatory and unconstitutional, CT Insider reports. The lawsuit takes particular aim at provisions that prioritize social equity applicants for the state’s cannabis industry licenses. The plaintiff, Brant Smith, who owns and operates an 80,000-square-foot greenhouse in Cheshire that he dedicated to hemp cultivation after the crop was federally legalized in 2018, claims in the suit that federal law prohibits the state from excluding cannabis applicants based on their location or residence. Attorney Genevieve Park Taylor, who represents Smith, suggested that Connecticut’s restrictions on cannabis licensing is “unequal and a little unbalanced.” “Everybody gets a chance or nobody gets a chance, whether it’s cantaloupes, cannabis or cabbage,” Taylor said in the report. “By favoring in-state social equity individual applicants and discriminating against all others, including out-of-state applicants, Connecticut’s marijuana licensing program amounts to economic protectionism, and improperly serves to benefit only in-state economic interests in general and social equity individuals specifically.” — Excerpt from the lawsuit The suit references a federal appeals court ruling from August that found part of New York’s cannabis social equity rules to be unconstitutional. Specifically, the ruling determined that a policy blocking people with federal or out-of-state cannabis convictions from receiving social equity-based priority was unconstitutional. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

A cannabis researcher presented findings that legalization of marijuana does not increase youth use. He also discussed issues with roadside impairment tests, the risk of false positives for THC from CBD products, and the need for more specific regulation of cannabinoids based on their effects rather than just THC levels. The talk emphasized differentiating cannabis products by their behavioral and health impacts and called for more research and quality control in the industry. < Back Marijuana Legalization Doesn’t Increase Youth Use, Top Researcher Says At Federal Meeting Jul 22, 2025 Ben Adlin Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link At a webinar hosted by the federal Substances and Mental Health Services Administration (SAMHSA) last week, a leading cannabis researcher threw cold water on the notion that legalizing marijuana leads to increases in youth use of the drug. He also touched on problems with roadside assessments of cannabis impairment, the risk of testing positive for THC after using CBD products and the need for more nuanced regulation around cannabinoids themselves. The public talk, from Ryan Vandry, an experimental psychologist and professor at Johns Hopkins University’s Behavioral Pharmacology Research Unit, was aimed at providing continuing education on marijuana for healthcare professionals. Titled “Behavioral Pharmacology of Cannabis – Trends in Use, Novel Products, and Impact,” it focused primarily on how variables like dosage, product formulation, mode of administration and chemical components such as terpenes can influence the drug’s effects. Vandry began by noting that marijuana is the most commonly used illicit drug in the United States. While self-reported consumption by adults has risen as more states have legalized in recent years, he noted, use by youth has generally remained flat or fallen. “Use among youth is one of the biggest areas of concern related to the legalization and increased accessibility of cannabis,” he said, “but surprisingly, that cohort has actually maintained relatively stable [for] both past-year and daily use.” Pointing to data from California going back to 1996, when the state ended prohibition for medical patients, Vandry said there has “really been no change in the rates of cannabis use among eighth, 10th or 12th graders. And in fact, in very recent years, we’ve seen a decrease in rates of consumption.” The researcher repeatedly emphasized the need for policymakers and health experts to differentiate between different kinds of cannabis, focusing less on delta-9 THC levels—which currently distinguish hemp from marijuana at the federal level—and more on a given product’s physical and cognitive impacts. “There is a gap between our understanding of these products and the evolution of retail cannabis products,” Vandry said. “The cannabis industry is driving diversity through competition, and scientifically, we’re having a hard time keeping up with the diversity of products that are coming out.” In general, he called for differentiating between THC-dominant products, CBD dominant products and other cannabinoid products based on their behavioral and health effects. THC and similar cannabinoids—including delta-8 THC, which is usually derived from legal hemp—exhibit characteristics typical of drugs of abuse, Vandry said, such as substance use disorders, withdrawal and impairment. “CBD is a very different animal,” he continued, noting that research shows “no evidence” of impairment or problem use, even when administered alongside very small amounts of THC. Another cannabinoid, CBG, “looks surprisingly similar to CBD in that it really doesn’t produce THC-like effects,” he said, citing a colleague’s research. But Vandry pointed to the current legal distinction between delta-8 THC and delta-9 THC—which both cause psychoactive effects—as an example of where regulations lag behind cannabis science. While delta-8 is metabolized more quickly in the body and is often described as less potent, a study he was involved in “showed…that if you just take double the dose of delta-8, you can get the exact same effects as delta-9,” he said. “But again, these two chemicals exist in extremely different areas in terms of federal policy and regulation,” the researcher continued. “Delta-9 THC is a Schedule I drug, and delta-8 THC is completely unscheduled if derived from hemp.” Another area where current policies are inadequate is evaluating marijuana-related impairment. Vandry and colleagues looked at three standard field sobriety tests used by law enforcement and found that even people who were administered THC and showed signs of impaired psychomotor ability could pass the common screening tests. Subjects given a 25 milligram dose of THC, meanwhile, which Vandry said caused observable impairment, often tested below per se THC blood limits, especially when the cannabinoid was taken orally. “Blood levels and blood concentrations of THC after oral ingestion are very low compared to the peak levels with inhalation, despite relatively equal pharmacodynamic effects,” he explained. In one experiment, people given 25 mg of THC registered a peak concentration of only two nanograms THC per milliliter of blood, “which, in some areas, is less than the per se cutoff for detection of impairment.” People who combined alcohol and marijuana also showed significant impairment even when neither their blood alcohol nor THC levels rose above per se limits. “This is a public health issue that we need to work to resolve and figure out,” Vandry said. While roadside tests could in some cases be missing signs of impairment, other tests might incorrectly lead to false positives. For example, many CBD products contain very small amounts of THC. Vandry said that in research, people who took similar products sometimes ended up testing positive for the metabolite used in urine drug tests to screen for marijuana use. “In many cases,” he said, the positive test came “after a single acute dose, and in most cases, after chronic dosing for two weeks.” Typically positive tests would cease after a few days of the person stopping use, but some people were still testing positive for THC use a week later. Terpenes—often pointed to by cannabis connoisseurs as responsible for modulating the experience of a particular strain or product—are a complicated matter that scientists are still sorting out, Vandry said. For example, he noted that famed cannabis researcher Ethan Russo promoted the notion “based on the idea of the entourage hypothesis,” which asserts that various chemicals in cannabis modulate the overall experience. Today, “a lot of marketing and advertising in the cannabis industry will make claims that specific terpenes do or promote certain types of therapeutic or beneficial effects above and beyond cannabis itself,” Vandry explained. Sometimes that’s supported by evidence, while other times it’s not, he said. For example, in an experiment Vandry and Russo collaborated on, subjects were given the terpene D-limonene along with 30 mg doses of pure, inhaled THC. “As we added doses of limonene to it, we got dose-orderly reductions in subjective ratings of anxiety and paranoia and the subjective feeling that their heart was racing,” he said, “but the overall magnitude of the drug effect was unchanged, cognitive impairment was unchanged… It seems here that limonene has a very specific non-cannabinoid mechanism by which it can attenuate the anxiety or panic-inducing effects of high doses of THC.” By contrast, similar testing showed little evidence for the claimed effects of another terpene, alpha-pinene, which the cannabis industry sometimes promotes as reducing anxiety, easing breathing and counteracting the memory-impairing effects of THC. “We didn’t really see any effect there,” Vandry said. “In contrast to the D-limonene study, we really saw no significant effect of alpha-pinene addition to delta-9 THC…on subjective drug effects, memory [effects] of any sort or cardiovascular effects.” Other issues the webinar touched on included psychosis and schizophrenia, differences in cannabis effects between male and female subjects as well as the need for more research and increased quality control around cannabis. With regard to what some have claimed is a causal link between marijuana and schizophrenia, Vandry was skeptical, noting that although in recent years, “past-year cannabis use has doubled in the U.S., the rate of schizophrenia has remained absolutely stagnant.” He acknowledged that there is “undoubtedly a strong correlation between heavy cannabis use and earlier onset of psychosis, and psychosis severity” but said “the causality on someone who would not otherwise develop psychosis is still questionable.” Vandry also warned that cannabis use disorder is a very real public health issue, with cessation rates similar to other drugs of abuse, such as nicotine or alcohol. Further, there’s some evidence that “females tend to react to the drug differently.” “They metabolize the drug differently, they progress more rapidly from first use to problematic use and are more treatment-resistant,” he explained, adding that female users also “tend to have greater withdrawal symptoms than men.” He also cautioned against focusing on THC potency levels in marijuana products, saying that overall dose, not potency, is what matters. “What we see is that people will adjust their use behavior based on the potency of the product,” the researcher said, explaining a concept known as self-titration. “If you gave someone five percent flower and 30 percent flower, your routine frequent daily user is going to smoke much more of the five percent to get to about the same dose.” “I think it’s more challenging for people to titrate their use of a high-potency product, but it’s the dose, not the concentration of the product,” he said. Effects can also vary by diet, especially when cannabis products are administered orally. For example, “cannabinoids taken with a high fat meal are absorbed much greater than if they’re taken on an empty stomach, which is the opposite of what is the case for most medications,” Vandry said. Cannabinoids can also interact with drugs like alcohol or even caffeine. The gaps between policy and scientific understanding underscores what Vandry said was a need for more investment in research, data collection and product testing and standardization. “We need to do a better job in figuring out abuse liability across these different types of products and get regulation that makes sense, that’s product-specific and dose-specific and formulation- and route-specific,” he said. “We need better control on quality control in terms of retail products and understanding these minor cannabinoids and terpenes.” “I kind of already said this,” Vandry concluded, but “I’d really like to see regulation not be on cannabis broadly, but on THC-dominant cannabis, CBD-dominant cannabis and other types of products, because the current policy really misses the point, where you have delta-8 on one end of the spectrum and delta-9 on the other.” Another recently published deep dive into the chemical components of cannabis looked at what gives products their distinctive flavors and aromas, examining how they’re affected by genetic makeup, cultivation methods and post-harvest processing. The goal, it said, is to “support advancements in breeding programs, enhance product quality control, and guide future research in cannabis sensory science.” Amid an upswing in marijuana research in the post-prohibition era, researchers are still unlocking new secrets about the cannabis plant. Researchers earlier this year, for example, announced that they successfully identified a new cannabinoid—cannabielsoxa—produced by the marijuana plant as well as a number of other compounds “reported for the first time from the flowers of *C. sativa*.” Other research in 2023, published by the American Chemical Society, identified “previously undiscovered cannabis compounds” that challenged conventional wisdom of what really gives cannabis varieties their unique olfactory profiles. As for other recent cannabis research, scientists reported in May that they identified 33 “significant markers” in the cannabis genome that “significantly influence cannabinoid production”—a finding they say promises to drive the development of new plant varieties with specific cannabinoid profiles. Among the findings were what the paper called a “massive” set of genes on one plant chromosome that involved about 60 megabases (Mb) and was associated specifically with THC-dominant cannabis strains. The article said the results “offer valuable guidance for *Cannabis *breeding programs, enabling the use of precise genetic markers to select and refine promising *Cannabis* varieties.” While research into marijuana has exploded in recent years as the result of more jurisdictions legalizing the drug for medical and adult use, it’s unclear how the Trump administration’s priorities will impact that trend. For example, under the new administration, “marijuana” is also now one of nearly two dozen “controversial or high-profile topics” that staff and researchers at the National Cancer Institute (NCI) are required to clear with higher-ups before writing about. The post Marijuana Legalization Doesn’t Increase Youth Use, Top Researcher Says At Federal Meeting appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

This content summarizes Halloween-themed cannabis products and strains, including LEVIA Bloody Orange seltzer, Grön’s Bite Club edibles, COAST Cookies & Scream bar, URSA x Slightly Stoopid vape, and Hometown Hero Midnight Gummies. It also highlights four thematically relevant strains (Phantom OG, Ghost Train Haze, Zombie OG, Monster Cookies) and offers marketing advice for retailers, such as using limited-edition products and creating spooky displays to drive engagement. < Back Boo-tanical Bliss: Frightfully Fun Cannabis Finds for Halloween 2025 Oct 24, 2025 Taylor Engle MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The treats: frightfully fun products 🎃 LEVIA Bloody Orange seltzer *Bloody good fun in every bubble* LEVIA’s fan-favorite Bloody Orange seltzer returns for Halloween, infused with the brand’s Achieve Sativa blend. The citrusy zero-sugar, zero-calorie drink delivers a fast-acting lift — ideal for festive nights. Retailers can tap into the fun with themed displays, limited-time giveaways, and the #SpreadtheLEVIA campaign, which drives community engagement online. Grön’s Bite Club *Join if you dare* Grön’s new Bite Club collection gives vampires something to sink their teeth into. The woman-led edibles brand unveils Nocturnal Nectar Pearls and Vampire’s Kiss MEGA. Online giveaways and an interactive site deepen brand connection while fueling late-night cravings. COAST Cookies & Scream bar *Hauntingly good chocolate* COAST Cannabis Co. stirs up indulgence with Cookies & Scream, a white-chocolate-and-cocoa wafer bar made with full-spectrum oil. Ethically sourced and artfully eerie, it’s limited-edition luxury with bite. URSA x Slightly Stoopid skull-wrapped vape *Rock ’n’ roll spirits* URSA teamed with Slightly Stoopid for a skull-studded vape cartridge packed with live resin flavor (Apricot Papaya × Strawberry DQ). A sativa-forward high with big Halloween energy. Hometown Hero Midnight Gummies *Midnight munchies, elevated* Hometown Hero returns with black, sugar-coated Delta-9 gummies flavored with Tiger’s Blood. Hemp-derived live rosin indica, shimmering presentation — a retail win for spooky-chic displays. Tastebudz Halloweed drops *Collectible chills, capped at 100* Tastebudz and Supernatural Seeds each drop four spooky strains (100 packs each) bundled with stickers, posters, and hauntingly good branding. For retailers: scarcity + creativity = buzz. Skate with Spherex *A high roll(er) revival* From a 75-person roller party to a 700+ person Halloween blowout, Spherex’s Denver bash features costumes, aura photography, and live art collabs. It’s experiential marketing done right. [image: Preloader image] [image: LEVIA Bloody Orange cannabis-infused seltzer with Halloween-themed packaging, a seasonal limited-release sativa beverage for festive promotions.] LEVIA Bloody Orange cannabis-infused seltzer with Halloween-themed packaging, a seasonal limited-release sativa beverage for festive promotions. [image: Grön Vampire’s Kiss MEGA gummy, a Halloween-themed sativa edible infused with full-spectrum cannabis and CBC extract in limited seasonal packaging.] Grön Vampire’s Kiss MEGA gummy, a Halloween-themed sativa edible infused with full-spectrum cannabis and CBC extract in limited seasonal packaging. [image: COAST Cannabis Co. Cookies & Scream white chocolate bar drizzled with red cocoa and presented with eerie Halloween cookie styling.] COAST Cannabis Co. Cookies & Scream white chocolate bar drizzled with red cocoa and presented with eerie Halloween cookie styling. [image: URSA Extracts' Stoopid Fruits live resin vape cartridge with skull-themed Halloween packaging created in collaboration with Slightly Stoopid.] URSA Extracts' Stoopid Fruits live resin vape cartridge with skull-themed Halloween packaging created in collaboration with Slightly Stoopid. [image: Supernatural Seeds Phantom Fuel artwork featuring a ghostly character and psychedelic Halloween design for a limited-edition cannabis seed drop.] Supernatural Seeds Phantom Fuel artwork featuring a ghostly character and psychedelic Halloween design for a limited-edition cannabis seed drop. [image: Hometown Hero Midnight Delta-9 live rosin gummies in Halloween limited-edition packaging with Tiger’s Blood flavor and spooky seasonal styling.] Hometown Hero Midnight Delta-9 live rosin gummies in Halloween limited-edition packaging with Tiger’s Blood flavor and spooky seasonal styling. *Carousel placeholder – styled for dark theme* The strains: frightfully good flower 👻 Phantom OG *A ghostly classic* Citrusy and piney with a minty undertone, Phantom OG delivers euphoria followed by cozy body warmth. It’s perfect for cool nights and candlelit seshes. *Why stock it: High THC (20–24%) and “phantom” branding make it a natural seasonal pick.* Ghost Train Haze *Full speed ahead* This powerhouse (Ghost OG × Neville’s Wreck) creates a sativa-forward rush of citrus and floral spice. It’s energetic, creative, and conversation-worthy. *Why stock it: Its name alone draws attention, but the uplifting effects ensure repeat sales.* Zombie OG *Dead tired in the best way* This heavy indica (OG Kush × Blackberry) brings a deep, relaxing stone ideal for post-party wind-downs. *Why stock it: The name + the knockout effect = perfect late-night Halloween synergy.* Monster Cookies *Dessert with bite* A cross of GSC × Granddaddy Purple, this hybrid, also known as Cookie Monster, blends sweet grape, berry, and earthy aromas with vanilla dessert notes to create mellow, relaxing vibes. *Why stock it: Approachable, tasty, and thematically on-point — a perfect closer for any “spooky” menu.* Halloween’s charm lies in its balance of nostalgia and novelty, and cannabis brands are mastering that mix. This year’s seasonal drops don’t just satisfy sweet tooths and THC cravings; they also reveal how smart marketing and storytelling can turn limited runs into long-term loyalty. ------------------------------ Halloween Cannabis FAQ: Consumer demand, retail trends, and product insights Do dispensaries really do Halloween promotions? Yes. Limited-edition products, bundles, and events help brands drive engagement and refresh shelf appeal in Q4. What are the best cannabis products for Halloween 2025? Top picks include *Grön’s Bite Club*, *COAST’s Cookies & Scream*, and *Hometown Hero Midnight Gummies*. Can hemp brands participate in Halloween marketing? Absolutely. Hemp-derived vapes, gummies, and drinks can go seasonal while staying compliant across states. Which strains fit a Halloween theme? Ghost Train Haze, Zombie OG, Monster Cookies, and Phantom OG market themselves with name + effect synergy. How can retailers make the most of spooky season? Create spooky displays, run themed events, and feature time-limited collaborations that create urgency and talkability. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

A local dispensary achieved 30% delivery sales in two months and plans to become Brooklyn's largest cannabis delivery service by summer 2026. < Back Greenpoint Dispensary Green Apple Eyes Brooklyn Delivery Dominance After Explosive Growth Sep 17, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The local dispensary achieved 30% delivery sales in just two months and is aiming to become Brooklyn’s largest cannabis delivery service by summer 2026. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

An Alabama appellate court blocked a lower court ruling preventing state regulators from issuing medical cannabis permits. An appeals court ruling could help restart Alabama medical cannabis licensing. < Back Appeals court ruling could help restart Alabama medical cannabis licensing May 23, 2025 Chris Roberts MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link An Alabama appellate court has blocked a lower court’s ruling that is preventing state regulators from issuing coveted vertically integrated medical cannabis permits. Appeals court ruling could help restart Alabama medical cannabis licensing is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5

The U.S. Supreme Court agreed to hear *U.S. v. Hemani*, a case challenging the constitutionality of a federal law (Section 922(g)(3)) that prohibits people who use marijuana or other illegal drugs from buying or possessing firearms, based on the Second Amendment. The Justice Department, which supports the ban, specifically requested the Supreme Court review this case. The defendant in *Hemani* is a user of both marijuana and cocaine. The law bans firearm possession for anyone who is an "unlawful user of or addicted to any controlled substance," although federal courts have recently cast doubt on the law's constitutionality, with several lower courts ruling against the ban, citing a lack of historical precedent for such a broad restriction on Second Amendment rights. < Back Supreme Court Agrees To Hear Case On Gun Rights Of People Who Use Marijuana And Other Illegal Drugs Oct 20, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The U.S. Supreme Court has agreed to hear a case on the constitutionality of a federal law prohibiting people who use marijuana or other drugs from buying or possessing firearms. The Trump administration has argued that the policy “targets a category of persons who pose a clear danger of misusing firearm” and should be upheld. After several years of conflicting lower court rulings on related cases, justices on Monday granted cert in *U.S. v. Hemani *to settle the question of whether the ban—known as Section 922(g)(3)—is consistent with the Second Amendment. While the court on Monday also declined to take up a separate case on cannabis consumers’ gun rights, there are still several others pending a decision from the justices. But the choice to take up *Hemani *in particular is likely welcome news to the Justice Department, which has consistently defended the firearm prohibition and specifically requested that SCOTUS review that case instead of alternatives. That could be related to the fact that the defendant is not only a marijuana consumer but also a user of cocaine who’s sold drugs in the past, so it’s possible DOJ reasoned that he is a less sympathetic face for the issue. Defendants in the other cases were merely found in possession of both a firearm and marijuana. In June, U.S. Solicitor General D. John Sauer, an appointee of President Donald Trump, submitted a filing with the Supreme Court that said “Section 922(g)(3) complies with the Second Amendment,” and the statute “targets a category of persons who pose a clear danger of misusing firearms: habitual users of unlawful drugs.” The law “bars their possession of firearms only temporarily and leaves it within their power to lift the restriction at any time; anyone who stops habitually using illegal drugs can resume possessing firearms,” Sauer said. Notably, while the government mentions “habitual” users of illegal drugs 40 times in its filing, that word does not itself appear in 922(g)(3). The language of the statute prohibits anyone “who is an unlawful user of or addicted to any controlled substance” from purchasing or possessing firearms or ammunition. In a separate August filing for the case, the Justice Department also emphasized that “the question presented is the subject of a multi-sided and growing circuit conflict.” In seeking the court’s grant of cert, the solicitor general also noted that the defendant is a joint American and Pakistani citizen with alleged ties to Iranian entities hostile to the U.S., putting him the FBI’s radar. Now that the Supreme Court has agreed to take up *Hemani*, if justices declare 922(g)(3) constitutional, such a ruling could could mean government wins in the remaining cases. The high court on Monday denied a petition for cert in *U.S. v. Cooper*, while leaving pending decisions on *U.S. v. Daniels* and *U.S. v. Sam*. The justices were scheduled to discuss all of the cases at a closed-door meeting last Friday. The court also recently denied a petition for cert in another gun and marijuana case, *U.S. v. Baxter, *but that wasn’t especially surprising as both DOJ and the defendants advised against further pursing the matter after a lower court reinstated his conviction for being an unlawful user of a controlled substance in possession of a firearm. A number of federal courts in recent years have cast doubt on the legality of § 922(g)(3), finding generally that while the ban on gun ownership among drug users may not be entirely unconstitutional, there’s scant historical precedent for such a broad restriction of Second Amendment rights on an entire a category of people. Meanwhile, in recent interviews with Marijuana Moment, several Republican senators shared their views on the federal ban on gun possession by people who use marijuana—with one saying that if alcohol drinkers can lawfully buy and use firearms, the same standard should apply to cannabis consumers. Separately, the U.S. Court of Appeals for the Tenth Circuit last month sided with a federal district court that dismissed an indictment against Jared Michael Harrison, who was charged in Oklahoma in 2022 after police discovered cannabis and a handgun in his vehicle during a traffic stop. The case has now been remanded to that lower court, which determined that the current statute banning “unlawful” users of marijuana from possessing firearms violates the Second Amendment of the Constitution. The lower court largely based his initial decision on an interpretation of a Supreme Court ruling in which the justices generally created a higher standard for policies that seek to impose restrictions on gun rights. The ruling states that any such restrictions must be consistent with the historical context of the Second Amendment’s original 1791 ratification. The historical analogues that the Justice Department relied on to make the case that the ban is consistent included references to antiquated case law preventing Catholics, loyalists, slaves and Indians from having guns. The circuit court, for its part, said that “the government must show non-intoxicated marijuana users pose a risk of future danger” to support the current policy. “This inquiry, which may involve fact finding, is best suited for the district court.” Meanwhile, in the U.S. Court of Appeals for the Eleventh District, judges recently ruled in favor of medical cannabis patients who want to exercise their Second Amendment rights to possess firearms. As a recent report from the Congressional Research Service (CRS) explained the current legal landscape, a growing number of federal courts are now “finding constitutional problems in the application of at least some parts” of the firearms prohibition. In a recent ruling, a three-judge panel for the U.S. Court of Appeals for the Eighth Circuit vacated a defendant’s conviction and remanded the case back to a district court, noting that a retrial before a jury may be necessary to determine whether cannabis in fact caused the defendant to be dangerous or pose a credible threat to others. The Third Circuit separately said in a published opinion that district courts must make “individualized judgments” to determine whether 922(g)(3) is constitutional as applied to particular defendants. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Earlier this year, a federal judge in Rhode Island ruled that the ban was unconstitutional as applied to two defendants, writing that the government failed to establish that the “sweeping” prohibition against gun ownership by marijuana users was grounded in historical precedent. A federal judge in El Paso separately ruled late last year that the government’s ongoing ban on gun ownership by habitual marijuana users is unconstitutional in the case of a defendant who earlier pleaded guilty to the criminal charge. The court allowed the man to withdraw the plea and ordered that the indictment against him be dismissed. DOJ has claimed in multiple federal cases over the past several years that the statute banning cannabis consumers from owning or possessing guns is constitutional because it’s consistent with the nation’s history of disarming “dangerous” individuals. In 2023, for example, the Justice Department told the U.S. Court of Appeals for the Third Circuit that historical precedent “comfortably” supports the restriction. Cannabis consumers with guns pose a unique danger to society, the Biden administration claimed, in part because they’re “unlikely” to store their weapon properly. Meanwhile, some states have passed their own laws either further restricting or attempting to preserve gun rights as they relate to marijuana. Recently a Pennsylvania lawmaker introduced a bill meant to remove state barriers to medical marijuana patients carrying firearms. Colorado activists also attempted to qualify an initiative for November’s ballot that would have protected the Second Amendment rights of marijuana consumers in that state, but the campaign’s signature-gathering drive ultimately fell short. As 2024 drew to a close, the ATF issued a warning to Kentucky residents that, if they choose to participate in the state’s medical marijuana program that’s set to launch imminently, they will be prohibited from buying or possessing firearms under federal law. The official said that while people who already own firearms aren’t “expected to” turn them over if they become state-legal cannabis patients, those who “wish to follow federal law and not be in violation of it” must “make the decision to divest themselves of those firearms.” Since then, bipartisan state lawmakers have introduced legislation that would urge Kentucky’s representatives in Congress to amend federal law to clarify that users of medical marijuana may legally possess firearms, though no action has since been taken on that bill. Kentucky Gov. Andy Beshear (D) said in January that he supported the legislature’s effort to urge the state’s congressional delegation to call for federal reforms to protect the Second Amendment rights of medical marijuana patients, but the governor added that he’d like to see even more sweeping change on the federal level. The post Supreme Court Agrees To Hear Case On Gun Rights Of People Who Use Marijuana And Other Illegal Drugs appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cookies & Alt Sol "Hollywood" Strain Review - Takoma Wellness Center As the name suggests, the Hollywood strain exudes the glitz and glamor of its namesake city. Grown by Alt Sol and now available at Takoma... Animal Face by RYTHM Strain Review (Maryland Recreational) Animal Face, cultivated by RYTHM, is a remarkable strain making its rounds at RISE dispensary in Silver Spring, Maryland. My awesome budt... Pink Passion - Goldflower, Largo (Florida Medical) At Goldflower Dispensary in Largo, Florida, this Pink Passion caught my eye for its understated elegance—medium spear-shaped buds in a deep purple shade, lightly threaded with orange hairs and coated in a moderate layer of clear trichomes that give it a subtle, sticky sheen. Grown indoors by DH Farms under Doghouse's banner, this hybrid clocks in at 23.6% total THC, hinting at a session that's engaging but not exhausting... 1 2 3 4 5